{"product_id":"gl-s-survodutide-10mg","title":"GL-S (Survodutide) 10mg","description":"\u003ch1\u003eGL-S Molecule (SUVODUTIDE)\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003e(Prescription Only, Free Consultation Required)\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003eDual-Receptor Therapy for Fat Loss, Appetite Control \u0026amp; Metabolic Optimization\u003c\/h3\u003e\n\u003chr\u003e\n\u003ch1\u003eFormulation\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003eGL-S 10\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e1 × 10mg GL-S Vial\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach vial contains:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e10mg GL-S (Suvodutide)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e1mL total volume\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eConcentration: \u003cstrong\u003e10mg \/ 1mL (10mg\/mL)\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eTotal Package Contents:\u003c\/strong\u003e 10mg GL-S (1mL total)\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eClassification:\u003c\/strong\u003e Prescription Only – Requires Provider Consultation \u0026amp; Approval\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003eWhat Is GL-S Therapy?\u003c\/h1\u003e\n\u003cp\u003eGL-S (Suvodutide) is a prescription dual-receptor metabolic therapy that activates two key physiological pathways involved in appetite regulation, energy expenditure, and fat metabolism:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eGLP-1 (Glucagon-Like Peptide-1) Receptor\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eGlucagon Receptor\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eUnlike traditional GLP-1 therapies that primarily suppress appetite, GL-S combines the well-established appetite-reducing effects of GLP-1 receptor activation with glucagon receptor stimulation, which promotes increased energy expenditure and fat oxidation. These complementary mechanisms are designed to improve body composition through both reduced caloric intake and enhanced metabolic activity.\u003c\/p\u003e\n\u003cp\u003ePotential benefits include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eSignificant appetite suppression\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eAccelerated fat loss\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eIncreased calorie expenditure\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eEnhanced fat oxidation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eImproved insulin sensitivity\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eReduction in visceral fat\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eImproved metabolic flexibility\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003ePotential improvement in liver fat accumulation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eLong-term body composition improvements\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eGL-S represents an emerging generation of metabolic therapy designed for provider-directed weight management and comprehensive metabolic optimization.\u003c\/p\u003e\n\u003cp\u003eAll GL-S products require clinical consultation and prescription approval prior to dispensing.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e🔬 Research-Based Mechanisms\u003c\/h1\u003e\n\u003ch2\u003e🔥 Dual-Receptor Activation for Comprehensive Fat Loss\u003c\/h2\u003e\n\u003cp\u003eGL-S simultaneously activates the GLP-1 and glucagon receptors, creating complementary metabolic effects that target both sides of the energy balance equation.\u003c\/p\u003e\n\u003cp\u003eGLP-1 receptor activation reduces hunger, slows gastric emptying, and increases satiety, while glucagon receptor activation promotes increased energy expenditure and utilization of stored fat.\u003c\/p\u003e\n\u003cp\u003ePotential benefits include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eReduced hunger\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eIncreased satiety\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eGreater fat oxidation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eIncreased calorie expenditure\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eImproved metabolic efficiency\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eEnhanced body composition\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003ePotential preservation of resting metabolic rate during weight loss\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003ePhase II obesity studies have demonstrated placebo-adjusted body weight reductions approaching \u003cstrong\u003e15–19%\u003c\/strong\u003e, with continued improvements observed over longer treatment durations.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch2\u003e🩸 Improved Glycemic Control \u0026amp; Insulin Sensitivity\u003c\/h2\u003e\n\u003cp\u003eGL-S improves glucose regulation primarily through GLP-1 receptor activation while simultaneously supporting healthy insulin responsiveness.\u003c\/p\u003e\n\u003cp\u003ePotential benefits include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eImproved insulin sensitivity\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eReduced fasting glucose\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eLower HbA1c\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eImproved metabolic health\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eBetter nutrient partitioning\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eClinical studies have demonstrated meaningful improvements in glycemic control alongside significant body weight reduction.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch2\u003e🧠 Appetite Suppression \u0026amp; Craving Control\u003c\/h2\u003e\n\u003cp\u003eGL-S acts on appetite centers within the central nervous system to reduce hunger while increasing feelings of fullness.\u003c\/p\u003e\n\u003cp\u003eMany patients report:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eLess frequent hunger\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eEarlier fullness during meals\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eReduced food cravings\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eEasier adherence to calorie reduction\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eImproved long-term dietary consistency\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch2\u003e🧬 Increased Fat Oxidation \u0026amp; Energy Expenditure\u003c\/h2\u003e\n\u003cp\u003eOne of the distinguishing characteristics of GL-S is activation of the glucagon receptor.\u003c\/p\u003e\n\u003cp\u003eRather than relying solely on appetite suppression, glucagon receptor stimulation encourages the body to utilize stored fat while increasing daily calorie expenditure.\u003c\/p\u003e\n\u003cp\u003ePotential benefits include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eIncreased fat utilization\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eHigher daily energy expenditure\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eImproved metabolic flexibility\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eGreater visceral fat reduction\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eEnhanced body composition\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mechanism may help offset the metabolic slowing that commonly occurs during prolonged weight loss.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch2\u003e🫀 Potential Benefits for Liver Health\u003c\/h2\u003e\n\u003cp\u003eSuvodutide has demonstrated encouraging early clinical results in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).\u003c\/p\u003e\n\u003cp\u003eWeight reduction combined with reductions in liver fat content may contribute to improvements in overall metabolic health.\u003c\/p\u003e\n\u003cp\u003ePotential benefits include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eReduced hepatic fat accumulation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eImproved liver enzyme profiles\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eImproved insulin resistance\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eBetter overall metabolic function\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch1\u003e⚕️ Clinical Access \u0026amp; Provider Oversight\u003c\/h1\u003e\n\u003cp\u003eGL-S therapy requires ongoing provider supervision.\u003c\/p\u003e\n\u003cp\u003eTreatment includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eInitial consultation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003ePrescription approval\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eIndividualized dosing plan\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eGradual titration based on tolerance\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eFollow-up monitoring\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eRecommended laboratory evaluation may include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eHbA1c\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eFasting glucose\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eComprehensive Metabolic Panel (CMP)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eLipid Panel\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eLiver Function Tests (AST\/ALT)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch1\u003e💉 Dosing Protocol (GL-S Core 10)\u003c\/h1\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003e\u003c\/th\u003e\n\u003cth\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eTotal Medication\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e10mg GL-S\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePackage Contents\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e1 × 10mg vial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eConcentration\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e10mg \/ 1mL (10mg\/mL)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eDosing Equivalency\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10 units = 1mg GL-S\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePatient Type\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eInitial Therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch2\u003eInitial Therapy\u003c\/h2\u003e\n\u003cp\u003eGL-S Core 10 is designed for patients beginning dual-receptor metabolic therapy.\u003c\/p\u003e\n\u003cp\u003eA gradual dose escalation allows the body to adapt while minimizing gastrointestinal side effects and optimizing long-term treatment success.\u003c\/p\u003e\n\u003cp\u003eTypical weekly dosing includes:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eWeekly Dose\u003c\/th\u003e\n\u003cth\u003eInjection Volume\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0.5mg\u003c\/td\u003e\n\u003ctd\u003e5 units\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1mg\u003c\/td\u003e\n\u003ctd\u003e10 units\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1.5mg\u003c\/td\u003e\n\u003ctd\u003e15 units\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2mg\u003c\/td\u003e\n\u003ctd\u003e20 units\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2.5mg\u003c\/td\u003e\n\u003ctd\u003e25 units\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3mg\u003c\/td\u003e\n\u003ctd\u003e30 units\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3.5mg\u003c\/td\u003e\n\u003ctd\u003e35 units\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e4mg\u003c\/td\u003e\n\u003ctd\u003e40 units\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e4.5mg\u003c\/td\u003e\n\u003ctd\u003e45 units\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e5mg\u003c\/td\u003e\n\u003ctd\u003e50 units\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eYour provider will individualize dosing based on treatment response, body composition goals, medication tolerance, and overall metabolic progress.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch2\u003eDose Adjustments\u003c\/h2\u003e\n\u003cp\u003eRemain on the current dose while progress continues.\u003c\/p\u003e\n\u003cp\u003eYour provider may recommend increasing by \u003cstrong\u003e5 units (0.5mg)\u003c\/strong\u003e if:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eWeight loss plateaus for two or more consecutive weeks\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eAppetite suppression significantly diminishes\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eTreatment continues to be well tolerated\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIf side effects occur:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eReduce by \u003cstrong\u003e5 units (0.5mg)\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eRemain at the lower dose until symptoms improve\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eResume upward titration only under provider guidance\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch2\u003eAdministration\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eRoute:\u003c\/strong\u003e Subcutaneous injection\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePreferred Site:\u003c\/strong\u003e Abdomen\u003c\/p\u003e\n\u003cp\u003eRotate injection sites regularly.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003eIdeal Use\u003c\/h1\u003e\n\u003cp\u003eGL-S Core 10 is intended for patients beginning therapy with a next-generation dual-receptor metabolic medication.\u003c\/p\u003e\n\u003cp\u003eIts combination of appetite suppression and increased energy expenditure may provide an effective option for individuals seeking significant fat loss while improving insulin sensitivity, metabolic flexibility, and overall body composition.\u003c\/p\u003e\n\u003cp\u003eBecause GL-S utilizes two complementary metabolic pathways, it offers a unique therapeutic approach that differs from traditional GLP-1 receptor agonists.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003eApproximate Treatment Duration\u003c\/h1\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eWeekly Dose\u003c\/th\u003e\n\u003cth\u003eWeekly Units\u003c\/th\u003e\n\u003cth\u003eApproximate Duration\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0.5mg\u003c\/td\u003e\n\u003ctd\u003e5 units\u003c\/td\u003e\n\u003ctd\u003e~20 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1mg\u003c\/td\u003e\n\u003ctd\u003e10 units\u003c\/td\u003e\n\u003ctd\u003e~10 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1.5mg\u003c\/td\u003e\n\u003ctd\u003e15 units\u003c\/td\u003e\n\u003ctd\u003e~7 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2mg\u003c\/td\u003e\n\u003ctd\u003e20 units\u003c\/td\u003e\n\u003ctd\u003e~5 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2.5mg\u003c\/td\u003e\n\u003ctd\u003e25 units\u003c\/td\u003e\n\u003ctd\u003e~4 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3mg\u003c\/td\u003e\n\u003ctd\u003e30 units\u003c\/td\u003e\n\u003ctd\u003e~3.3 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e4mg\u003c\/td\u003e\n\u003ctd\u003e40 units\u003c\/td\u003e\n\u003ctd\u003e~2.5 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e5mg\u003c\/td\u003e\n\u003ctd\u003e50 units\u003c\/td\u003e\n\u003ctd\u003e~2 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eActual treatment duration will vary based on individualized provider-directed dosing.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003eTypical Program Length\u003c\/h1\u003e\n\u003cp\u003eGL-S is commonly incorporated into a \u003cstrong\u003e3–12 month provider-guided metabolic optimization program\u003c\/strong\u003e, with reassessment every \u003cstrong\u003e8-12 weeks\u003c\/strong\u003e to evaluate progress, optimize dosing, monitor body composition changes, and determine the most appropriate long-term treatment strategy.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003eCompatible Therapy Stacks\u003c\/h1\u003e\n\u003ch3\u003eKPV\u003c\/h3\u003e\n\u003cp\u003eSupports gastrointestinal health, intestinal barrier integrity, and inflammatory balance, making it an excellent adjunct during metabolic therapy.\u003c\/p\u003e\n\u003ch3\u003eTesamorelin\u003c\/h3\u003e\n\u003cp\u003eSupports preservation of lean muscle mass while promoting visceral fat reduction, complementing body composition improvements achieved with GL-S.\u003c\/p\u003e\n\u003ch3\u003eMOTS-C\u003c\/h3\u003e\n\u003cp\u003eEnhances mitochondrial function, insulin sensitivity, metabolic flexibility, cellular energy production, and exercise performance while supporting healthy fat utilization.\u003c\/p\u003e\n\u003ch3\u003eGHK-Cu\u003c\/h3\u003e\n\u003cp\u003eSupports tissue repair, recovery, collagen production, and overall regenerative health during comprehensive metabolic optimization.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e📦 Every Order Includes\u003c\/h1\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e1 × 10mg GL-S vial (1mL)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eInsulin syringes\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eAlcohol swabs\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eSharps disposal bag\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003ePrinted dosing, storage, reconstitution, and injection guide\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eOngoing access to a licensed prescribing provider for treatment support\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch1\u003e📧 Questions?\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003e\u003ca href=\"mailto:Admin@ProPeptides.com\"\u003eAdmin@ProPeptides.com\u003c\/a\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e480-400-6225\u003c\/strong\u003e\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e🛡️ Dual-Receptor Precision. Advanced Metabolic Therapy. Clinical Oversight.\u003c\/h1\u003e\n\u003cp\u003eGL-S Core 10 combines GLP-1 receptor activation with glucagon receptor stimulation to address multiple aspects of metabolic dysfunction through complementary physiological mechanisms. By reducing appetite while simultaneously increasing energy expenditure and fat oxidation, GL-S supports meaningful improvements in body composition, insulin sensitivity, and overall metabolic health.\u003c\/p\u003e\n\u003cp\u003eDesigned for provider-guided metabolic optimization, GL-S Core 10 offers a structured titration program with comprehensive clinical oversight. When combined with individualized nutrition, resistance training, regular body composition assessments, and ongoing follow-up, it provides a comprehensive approach to achieving sustainable fat loss and long-term metabolic wellness.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch3\u003eSelected References\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eTillner J, et al. \u003cstrong\u003eEffects of survodutide (BI 456906), a glucagon\/GLP-1 receptor dual agonist, in adults with overweight or obesity:\u003c\/strong\u003e Phase II clinical trial data.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eBoehringer Ingelheim \u0026amp; Zealand Pharma. \u003cstrong\u003eSYNCHRONIZE™ Clinical Development Program\u003c\/strong\u003e for obesity and metabolic disease.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003ePhase II MASH\/MASLD studies evaluating liver fat reduction and metabolic outcomes with survodutide.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Pro Peptides","offers":[{"title":"Default Title","offer_id":49335998185731,"sku":null,"price":279.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0769\/7848\/7555\/files\/Suvodutide10.png?v=1785203231","url":"https:\/\/www.propeptides.com\/products\/gl-s-survodutide-10mg","provider":"Pro Peptides","version":"1.0","type":"link"}